Team: Applied research using Omic Sciences, S.L. (AROMICS)
PI: Dr. Carmen Plasencia
Project: We recently patented a family of new chemical entities, derivatives of berberine, with activity as antitumor agents. First lead compound is advancing up to clinics to treat malignant mesothelioma. The PhD student will comprehensively contribute to the selection and optimization of a lead candidate, and to test it in pre-clinical models. Selection will be based on the in vitro and in vivo activity, modulation of specific targets and metabolic pathways, physicochemical and pharmacological aspects, with the objective of completing the preclinical development stage for the selected candidate(s). The candidate will employ cellular and molecular biology techniques as well as pharmaocological aspects (ADMET) to elucidate the efficacy of the compounds and their properties to advance into further development stages.
As part of our MSCA-ESR training on complementary skills we got to leave the wet lab to explore what happens on the other side of the bench and to learn what it means to be a scientific editor. This is our story.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 766214.
Bellvitge Biomedical
Research Institute (IDIBELL)
Hospital Duran i Reynals, 3a planta
Gran Via de l’Hospitalet, 199
08908 L’Hospitalet del Llobregat
Barcelona, Spain
